This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RTRX Travere Therapeutics (RTRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock About Travere Therapeutics Stock (NASDAQ:RTRX) 30 days 90 days 365 days Advanced Chart Get Travere Therapeutics alerts:Sign Up Key Stats Today's Range$16.25▼$16.6050-Day Range$24.25▼$28.1852-Week Range$8.98▼$24.96Volume1.23 million shsAverage Volume412,277 shsMarket Capitalization$840.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA. Read More Receive RTRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RTRX Stock News HeadlinesTravere Therapeutics Inc.July 6, 2025 | barrons.comTravere Therapeutics Kicks Off “Play It Forward” Campaign for FSGS AwarenessJune 24, 2025 | msn.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.July 12 at 2:00 AM | Porter & Company (Ad)Travere Therapeutics’ sNDA for FILSPARI accepted by FDAMay 17, 2025 | uk.investing.comIBD 50 Stock Travere Therapeutics Nosedived On An FDA Decision — Here's WhyMay 16, 2025 | msn.comTravere Stock Nosedives As FDA Schedules Advisory Meeting For Kidney Drug's Supplemental Use: Retail Shrugs Off WorriesMay 16, 2025 | msn.comTravere Therapeutics Rallies To Buy Point As Kidney Drug Sales Rocket 182%; Anticipates FDA Priority Review For FSGS TreatmentMay 6, 2025 | msn.comTravere Therapeutics anticipates FILSPARI approval for FSGS by September 2025May 2, 2025 | msn.comSee More Headlines RTRX Stock Analysis - Frequently Asked Questions How were Travere Therapeutics' earnings last quarter? Travere Therapeutics, Inc. (NASDAQ:RTRX) issued its quarterly earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.15. Travere Therapeutics had a negative net margin of 49.13% and a negative trailing twelve-month return on equity of 36.38%. What other stocks do shareholders of Travere Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Travere Therapeutics investors own include CVS Health (CVS), Bristol Myers Squibb (BMY), Gilead Sciences (GILD), Novavax (NVAX), TG Therapeutics (TGTX), Dynavax Technologies (DVAX) and Intercept Pharmaceuticals (ICPT). Company Calendar Last Earnings11/05/2020Today7/12/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:RTRX CIK1438533 Webwww.retrophin.com Phone(888) 969-7879FaxN/AEmployees221Year FoundedN/AProfitability EPS (Trailing Twelve Months)($3.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$146.43 million Net Margins-49.13% Pretax MarginN/A Return on Equity-36.38% Return on Assets-14.90% Debt Debt-to-Equity Ratio0.66 Current Ratio7.23 Quick Ratio7.14 Sales & Book Value Annual Sales$175.34 million Price / Sales4.80 Cash FlowN/A Price / Cash FlowN/A Book Value$5.15 per share Price / Book3.20Miscellaneous Outstanding Shares51,052,000Free FloatN/AMarket Cap$840.83 million OptionableNot Optionable Beta0.67 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:RTRX) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
